主页 > 医药科学 >
【medical-news】脑癌疫苗使用范围扩大
NEW YORK (Reuters) - A promising vaccine to treat brain cancer developed by Avant Immunotherapeutics Inc may also hold promise against numerous other types of cancer, Interim Chief Executive Anthony Marucci said in an interview.
Researchers on Monday said Avant's vaccine, licensed by Pfizer Inc in April, more than doubled the survival time in patients, with the most common and deadly type of brain tumor in a clinical trial.
Marucci, whose company is guaranteed an undisclosed double- digit royalty on Pfizer's future sales of the product, said the world's largest drugmaker has the money and could have the desire to greatly widen the scope of research on the vaccine.
For treatment of brain cancer alone, Marucci said the vaccine could garner annual U.S. sales of at least $500 million and have significant sales potential in overseas markets.
路透社纽约消息 生物制造商Avant 免疫疗法公司（Avant Immunotherapeutics Inc）临时执行总裁安东尼•莫路西（Anthony Marucci）在接受采访时说：一种由该公司开发的疫苗不仅有望治疗脑肿瘤，也可能有望治疗其它类型众多的肿瘤。
研究者在周一称，由辉瑞公司在四月份授权的Avant疫苗，在一项临床试验中使患有最常见致命脑肿瘤的患者的生存期倍增。
莫路西说，辉瑞作为全球最大的药品生产商财力雄厚，并有大力拓宽该疫苗研究范围的强烈愿望。莫路西的公司已获保证，在辉瑞对该产品的未来销售中，辉瑞将向其支付百分点超过两位数的特许开发权利金，但未透露具体的两位数数字。
对于仅治疗脑瘤而言，莫路西说该疫苗可以实现美国市场年销售额至少5亿美元的目标，而且海外市场销售潜力也十分巨大。
（Docofsoul 译于 2008年6月6日）
Avant：脑瘤疫苗有着更为广阔的前景
NEW YORK (Reuters) - A promising vaccine to treat brain cancer developed by Avant Immunotherapeutics Inc may also hold promise against numerous other types of cancer, Interim Chief Executive Anthony Marucci said in an interview.
路透社纽约消息 生物制造商Avant 免疫疗法公司（Avant Immunotherapeutics Inc）临时执行总裁安东尼•莫路西（Anthony Marucci）在接受采访时说：一种由该公司开发的疫苗不仅有望治疗脑肿瘤，也可能有望治疗其它类型众多的肿瘤。
Researchers on Monday said Avant's vaccine, licensed by Pfizer Inc in April, more than doubled the survival time in patients, with the most common and deadly type of brain tumor in a clinical trial.
研究者在周一称，由辉瑞公司在四月份授权的Avant疫苗，在一项临床试验中使患有最常见致命脑肿瘤的患者的生存期倍增。
Marucci, whose company is guaranteed an undisclosed double- digit royalty on Pfizer's future sales of the product, said the world's largest drugmaker has the money and could have the desire to greatly widen the scope of research on the vaccine.
莫路西说，辉瑞作为全球最大的药品生产商财力雄厚，并有大力拓宽该疫苗研究范围的强烈愿望。莫路西的公司已获保证，在辉瑞对该产品的未来销售中，辉瑞将向其支付百分点超过两位数的特许开发权利金，但未透露具体的两位数数字。
For treatment of brain cancer alone, Marucci said the vaccine could garner annual U.S. sales of at least $500 million and have significant sales potential in overseas markets.
对于仅治疗脑瘤而言，莫路西说该疫苗可以实现美国市场年销售额至少5亿美元的目标，而海外市场销售潜力也十分巨大。
（Docofsoul 译于 2008年6月6日）
。 期待研发成功 脑肿瘤病理类型众多，发生机制搞清楚的很少，不知这种所谓“疫苗”有多大的效果。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-06 17:11
医学,生命科学网